期刊文献+

还原型谷胱苷肽治疗帕金森病大鼠模型的实验研究 被引量:5

Experimental study of reduced glutathione in treatment of Parkinson's disease rats
暂未订购
导出
摘要 目的观察还原型谷胱苷肽(GSH)治疗帕金森病(PD)大鼠模型的疗效。方法35只SD大鼠采用内侧前脑束注射6一羟多巴胺(6-OHDA)制作偏侧PD模型。术后第6周根据阿朴吗啡旋转试验将模型鼠分为部分PD组和完全PD组,各组再随机分为GSH亚组和对照亚组,并分别给予GSH或生理盐水腹腔注射,每日1次,共4周。治疗后第2周、4周、6周、8周进行阿朴吗啡旋转试验。结果共有27只大鼠制模成功,13只为部分PD模型,14只为完全PD模型;部分PDGSH亚组治疗后第4周、6周、8周阿朴吗啡旋转试验每分钟旋转次数较治疗前及相应的对照亚组显著减少(P〈0.05~0.01);完全PDGSH亚组较治疗前及相应的对照亚组无显著变化。结论GSH治疗6-OHDA所致的部分PD大鼠模型有效,对完全PD大鼠模型无效。 Objective To examine the effect of treatment with reduced glutathione(GSH) in 6-OHDA induced rat models of Parkinson's disease (PD). Methods 35 SD rats were received injection of 6-OHDA by medial forebrain bundle to make lateral PD models. According to rotation test induced by Apomorphine 6 weeks later, the model rats were divided into partial PD group and total PD group. Each group was further divided into reduced glutathione hormone (GSH) sub-group and control sub-group randomly. The sub-groups were treated intraperitoneally with GSH or normai saline every day for 4 weeks, respectively. The functional outcome of each group was measured using the Apemorphine induced rotation test at 2, 4, 6 and 8 weeks after treatment. Results Successful PD models were made in 27 of 35 rats, which included 13 partial PD models and 14 total PD models. The numbers of rotation per minute induced by Apemorphine at 4, 6 and 8 weeks after treatment with GSH in partial PD group were significantly lower than that before treatment and in the control sub-group (P 〈0. 05 ~0. 01 ). But in total PD group, no significant difference of rotation number was found after treatment with GSH compared with before treatment and the control sub-group. Conclusions GSH may improve neurological outcome of 6-OHDA induced partial PD model rats. But it is no effective for total PD model rats.
出处 《临床神经病学杂志》 CAS 北大核心 2006年第6期441-443,共3页 Journal of Clinical Neurology
关键词 帕金森病 还原型谷胱苷肽 旋转试验 Parkinson's disease reduced glutathione rotation test
  • 相关文献

参考文献15

  • 1[1]Asanuma M,Miyazaki I,Diaz-Corrales FJ,et al.Quinone formation as dopaminergic neuron-specific oxidative stress in the pathogenesis of sporadic Parkinson's disease and neurotoxin-induced parkinsonism[J].Acta Med Okayama,2004,58:221.
  • 2[2]Mercer LD,Kelly BL,Horne MK,et al.Dietary polyphenols protect dopamine neurons from oxidative insults and apoptosis:investigations in primary rat mesencephalic cultures[J].Biochem Pharmacol,2005,69:339.
  • 3徐耀,罗蔚锋.帕金森病自由基及抗氧化治疗研究进展[J].国外医学(神经病学.神经外科学分册),2002,29(1):87-90. 被引量:4
  • 4[4]Larumbe IR,Ferrer Valls JV,Vines Rueda JJ,et al.Case-control study of markers of oxidative stress and metabolism of blood iron in Parkinson's disease[J].Rev Esp Salud Publica,2001,75:43.
  • 5[5]Exter DT,Sian J,Rose S,et al.Indices of oxidative stress and mitochondrial function in individuals with incidental lewy body disease[J].Ann Neurol,1994,35:38.
  • 6[6]Bharath S,Hsu M,Kaur D,et al.Glutathione,iron and Parkinson's disease[J].Biochem Pharmacol,2002,64:1037.
  • 7[7]Brown TP,Rumsby PC,Capleton AC,et al.Pesticides and Parkin-son's disease--is there a link[J]?Environ Health Perspect,2006,114:156.
  • 8[8]Mandel S,Grunblatt E,Riederer P,et al.Neuroprotective strategies in Parkinson's disease:an update on progress[J].CNS Drugs,2003,17:729.
  • 9[9]Wu G,Fang YZ,Yang S,et al.Glutathione metabolism and its implications for health[J].J Nutr,2004,134:489.
  • 10[10]Botella JA,Ulschmid JK,Gruenewald C,et al.The Drosophila carbonyl reductase sniffer prevents oxidative stress-induced neurodegeneration[J].Curr Biol,2004,14:782.

二级参考文献21

  • 1Vatassery GT. Vitamin E and other endogenous antioxidants in the central nervous system. Geriatrics, 1998, 53 (Suppl) 1: s25-27.
  • 2Jin BK, Shin DY, Jeong MY. Melatonin protects nigral dopaminergic neurons from MPP+ neurotoxicity in rats. Neurosci Lett, 1998, 245(2): 61-64.
  • 3Verhagen Merman L, Del Dotto P, Blancher PJ, et al. Blockade of glutamatergie transmisson as treatment for dyskinesias and motor fluctuations in Parkinson's disease. Amino Acids, 1998, 14(1-3):75-82.
  • 4Unsicker KC, Suter Crazzolara, K Krieglstein. Neurotrophic roles of GDNF and related factors. Handbook Exp Pharmacol, 1999, 134:189-224. ???
  • 5Lingor P, Unsicker K, Krieglstein K. GDNF and NT-4 protect Midbrain Dopaminergic neurons from Toxic Damage by Iron and Nitric Oxide. Exp Neurol, 2000, 163(1): 55-62.
  • 6Cosi C, Marien M. Implication of poly (ADP-ribose) polymerase(PARP) in neurodegeneration and brain energy metabolism: Decreasea in mouse brain NAD + and ATP caused by MPTP are protected by the PARP inhibitor benzamide. Ann N Y Acad Sci, 1999, 890: 227-239.
  • 7Nakamura K, Wright DA, Wiatr T. Preferential resistance of dopaminergic neurons to the toxicity of glutathione depletion is independent of cellular glutathione peroxidase and is mediated by tetrahydrobiopterin. J Neurechem, 2000, 74(6): 2305-2314.
  • 8Dela Torre MR, Casado A, Lopez Femandoz ME, et al. Human aging brain disorders, role of antioxidant enzyme. Neurochem Res, 1996,21(8): 885-888.
  • 9Hattori N, Tanaka M, Ozawa T, et al. Immunohistochemical Studies, on Complexesl, Ⅱ, Ⅲ, and Ⅳ of Mitochondria in Parkinson's disease. Ann Neurol, 1991, 30(4): 563-572.
  • 10Jellinger KA. The role of iron in neurodegeneration Prospects for pharmecotherapy of Parkinson's disease. Drugs Aging, 1999, 14(2): 115-140.

共引文献17

同被引文献26

引证文献5

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部